| |
Original Artikel |
Datum |
Titel |
Autoren Alle Autoren |
| 1 |
[GO] |
2025―Apr―20 |
The Susceptibility of Klebsiella Pneumoniae Strains Isolated from COVID-19 Patients to Commercially Available Bacteriophage Medications |
B. I. Aslanov, A. E. Goncharov, S. D. Konev, A. S. Mochov, D. A. Azarov, E. А. Lebedeva, et al. (+6) A. V. Kuleshova, V. V. Kolodzhieva, E. N. Kolosovskaya, A. M. Nifontova, D, A. Lioznov |
| 2 |
[GO] |
2025―Apr―20 |
Antiviral Activity of 5-chloropyridin-3-yl-1h-indole-4-carboxylate (AMND) Against COVID-19 |
S. Ya. Loginova, V. N. Shсhukina, S. V. Savenko, V. V. Rubtsov, D. A. Kutayev, S. V. Borisevich, et al. (+6) V. A. Kovtun, N. I. Mosin, M. M. Muradov, V. L. Volkov, A. S. Belyaev, A. B. Predtechensky |
| 3 |
[GO] |
2025―Feb―10 |
Analysis of the Distribution Pattern of Genetic Biomarkers of Safety of Etiotropic Drugs for the Treatment of COVID-19 in Representatives of Ethnic Groups of the Volga Region and the Far East |
S. N. Tuchkova, Sh. P. Abdullaev, N. P. Denisenko, A. V. Kryukov, I. I. Temirbulatov, S. S. Suleymanov, et al. (+6) E. Y. Kitaeva, V. V. Shprakh, E. E. Sidukova, I. V. Sychev, K. B. Mirzaev, D. A. Sychev |
| 4 |
[GO] |
2024―Nov―22 |
Temporal Dynamics of the Resistome of the Intestinal Microbiota of a Healthy Population against the Background of COVID-19 |
A. V. Pavlenko, A. I. Manolov, Yu. I. Esin, A. L. Arkhipova, A. V. Vvedenskiy, A. V. Kudryavtsev, et al. (+5) E. A. Krieger, L. L. Shagrov, N. I. Belova, E. N, Ilyina |
| 5 |
[GO] |
2024―Nov―22 |
Dynamics of Matrix Metalloproteinase-9 Levels in the Novel Coronavirus Infection COVID-19 |
A. U. Sabitov, Yu. B. Khamanova, Yu. N. Moskaleva, E. Yu. Kamaev, P. L. Kuznetsov, M. D. Medvedeva |
| 6 |
[GO] |
2024―Jun―21 |
Comparative Analysis of the Antiviral Activity of Various Drugs Based on 6-Fluoro-3-Hydroxy-2-Pyrazinecarboxamide (Favipiravir) Against COVID-19 |
S. Ya. Loginova, V. N. Schukina, S. V. Savenko, V. V. Rubtsov, S. V. Borisevich, D. L. Chizhov, et al. (+5) G. L. Rusinov, E. V. Verbitskiy, V. N. Charushin, S. K. Kotovskaya, V. L. Rusinov |
| 7 |
[GO] |
2024―Apr―16 |
Epidemic situation and features of accompanying therapy in the treatment of socially significant infectious diseases in penitentiary populations before, during, and after the COVID-19 pandemic |
V. M. Kolomiets, N. A. Polshikova, A. Yu. Petrov, A. L. Kovalenko, E. V. Talikova |
| 8 |
[GO] |
2024―Apr―16 |
Efficacy and safety of oral antiviral therapy medications in the treatment of moderate and severe cases of COVID-19. Results of a comparative retrospective observational study |
A. U. Sabitov, E. P. Tikhonova, E. V. Esaulenko, P. L. Kuznetsov, A. A. Sharova, T. A. Yelistratova, et al. (+5) Yu. S. Kalinina, I. V. Andreeva, V. V. Basina, E. V. Oleinichenko, A. S. Edin |
| 9 |
[GO] |
2024―Jan―16 |
Cardiotoxic Drugs Used in the Treatment of COVID-19 |
A. S. Zmitrukevich, A. E. Mamedova |
| 10 |
[GO] |
2024―Jan―16 |
Present Strategy and Tactics of Antibacterial Therapy for Hospital Infections: Lessons Learned from the COVID-19 Pandemic |
S. D. Mitrokhin, A. V. Aleshkin, A. A. Galitskiy, A. S. Shkoda |
| 11 |
[GO] |
2023―Dez―27 |
Distribution of Genetic Factors Associated with Severe COVID-19 in Ethnic Groups of the Eastern Caucasus |
S. Р. Abdullaev, К. М.-В. Mammaev, N. Р. Denisenko, I. L. Temirbulatov, A. А. Kachanova, E. V. Mikhaylenko, et al. (+5) А. V. Kryukov, Т. Т. Valiev, К. В. Mirzaev, S. N. Mammaev, D. А. Sychev |
| 12 |
[GO] |
2023―Dez―27 |
Relief from Toxic Effects of Oxygen Using Succinates in Patients with COVID-19 Undergoing High-Flow Oxygen Therapy |
N. V. Govorova, S. V. Tsilina, I. A. Khilenko, V. V. Rezvykh, Yu. Р. Orlov |
| 13 |
[GO] |
2023―Okt―23 |
Non-Specific Means of Medical Protection Against COVID-19 |
T. E. Sizikova, E. V. Lebedinskaya, O. V. Chukhralya, A. A. Petrov, V. N. Lebedev, S. V. Borisevich |
| 14 |
[GO] |
2023―Okt―23 |
Dynamics of Reserve Antimicrobial Drug Consumption in Russian Hospitals: Impact of the COVID-19 Pandemic |
Y. M. Gomon, A. A. Kolbin, D. S. Budanov |
| 15 |
[GO] |
2023―Okt―23 |
Pharmacogenetic Markers of Favipiravir Safety in COVID-19 Treatment |
I. I. Temirbulatov, A. V. Kryukov, K. B. Mirzaev, N. P. Denisenko, S. P. Abdullaev, A. V. Petrova, et al. (+3) E. P. Tkach, A. V. Shipacheva, D. A. Sychev |
| 16 |
[GO] |
2023―Jul―18 |
A Systematic Review with Meta-Analysis and Indirect Comparison of the Effectiveness of COVID-19 Anti-Interleukin Therapy |
Yu. M. Gomon, A. S. Kolbin, A. M. Fahrutdinova, T. A. Usmanova, F. M. Sultanova, Yu. E. Balykina |
| 17 |
[GO] |
2023―Jul―18 |
Clinical and Laboratory Characteristics of Patients with COVID-19 on the Background of Cardiovascular Diseases |
Z. A. Kambachokova, Z. A. Akhkubekova, R. M. Aramisova, D. E. Altudova, L. A. Kagazheva, M. A. Shokueva, et al. (+5) A. A. Kambachokova, A. B. Kankulova, A. M. Urusbiev, Yusufzai Abdul Vadzhid, I. A. Kochesokova |
| 18 |
[GO] |
2023―Feb―11 |
Is There a Need to Widely Prescribe Antibiotics in Patients with COVID-19? |
N. A. Karoli, A. P. Rebrov |
| 19 |
[GO] |
2022―Dez―29 |
Antiviral Activity of The Preparation Meflokhin® Against COVID-19 |
S. Ya. Loginova, V. N. Shhukina, S. V. Savenko, S. V. Borisevich, K. N. Filin, I. A. Berzin, V. D. Gladkikh |
| 20 |
[GO] |
2022―Dez―29 |
Antimicrobial Therapy and COVID-19 - the 'Great Confrontation' |
A. A. Zaytsev, A. М. Makarevich |
| 21 |
[GO] |
2022―Nov―29 |
Antiviral Activity of Interferon alfa-2b and Taurine Combination Against SARS-CoV-2 <i>in vitro</i> |
N. P. Kartashova, A. V. Ivanina, E. A. Glubokova, I. N. Falynskova, A. A. Poromov, I. A. Leneva |
| 22 |
[GO] |
2022―Nov―18 |
The Effect of Carriage of <i>CYP3A5*3</i> and <i>CYP3A4*22</i> Polymorphic Variants on the Safety of Remdesivir Therapy in Patients with COVID-19 |
I. I. TEMIRBULATOV, A. V. KRYUKOV, K. B. MIRZAEV, N. P. DENISENKO, S. P. ABDULLAEV, A. S. ZHIRYAKOVA, et al. (+4) Y. V. SHEVCHUK, V. I. VECHORKO, O. V. AVERKOV, D. A. SYCHEV |
| 23 |
[GO] |
2022―Nov―18 |
The Problem of Comorbid Socially Significant Infections Under The Conditions of The COVID-19 Pandemic |
V. M. KOLOMIETS, N. A. POLSHIKOVA, A. L. KOVALENKO, E. P. PAVLENKO |
| 24 |
[GO] |
2022―Sep―10 |
Cycloferon as a Means for Prevention, Treatment, and Control of COVID-19: Multidisciplinary and Comparative Historical Aspects |
P. V. MAZIN, R. K. KHAFISIANOVA, V. P. MAZIN, A. A. GALKIN, A. K. OSKANOV |
| 25 |
[GO] |
2022―Sep―10 |
Immunogenicity of Vaccines Against SARS-CoV-2 In Patients With Rheumatic Diseases |
B. B. BELOV, N. V. MURAVYEVA, A. N. KULIKOV |
| 26 |
[GO] |
2022―Aug―07 |
Medical Rehabilitation of Elderly and Senior Patients with COVID-19-Associated Pneumonia |
M. I. Ivanova, V. M. Ivanov, Yu. M. Shcheglova, A. L. Kovalenko, E. V. Talikova |
| 27 |
[GO] |
2022―Apr―16 |
Neuroprotective Therapy for Neurological Complications of the Novel Coronavirus Infection COVID-19 |
Ju. L. Lukyanova, S. A. Lukyanov, K. G. Shapovalov |
| 28 |
[GO] |
2022―Apr―16 |
Antibacterial Therapy of Patients With COVID-19 During The Outpatient and Hospital Stages |
N. A. Karoli, A. V. Aparkina, E. V. Grigoryeva, N. A. Magdeeva, N. M. Nikitina, N. D. Smirnova, A. P. Rebrov |
| 29 |
[GO] |
2021―Okt―21 |
Seaweed-Derived Sulfated Polysaccharides as Potential Agents for Prevention and Treatment of Influenza and COVID-19 |
N. N. Besednova, T. N. Zvyagintseva, B. G. Andriukov, T. S. Zaporozhets, T. A. Kuznetsova, S. P. Kryzhanovsky, et al. (+2) L. G. Guseva, M. Yu. Shchelkanov |
| 30 |
[GO] |
2021―Okt―21 |
Problem of Drug Interactions in the Treatment of Patients with COVID-19 and Comorbid Conditions |
R. M. Aramisova, Z. A. Kambachokova, Z. A. Akhkubekova, L. L. Logvina, M. M. Sarbasheva, S. M. Chudopal, et al. (+4) L. B. Tlapshokova, L. M. Taukenova, A. R. Tambiev, K. R. Pshukov |
| 31 |
[GO] |
2021―Okt―21 |
COVID-19 Therapy: the Role of Antirheumatic Drugs |
M. A. Litvinova, N. V. Muravyeva, B. S. Belov |
| 32 |
[GO] |
2021―Okt―21 |
Study of Riamilovir Activity Against SARS-CoV-2 Infection In Syrian Hamsters |
S. V. Chepur, A. V. Smirnova, A. N. Kirienko, I. A. Myasnikova, B. A. Kanevsky, P. V. Sorokin |
| 33 |
[GO] |
2021―Aug―30 |
Possibilities of suppressing the cytopathogenic effect of SARS-CoV-2 coronavirus according to the results of the antiviral activity of Cytovir®-3 in vitro study |
V. S. Smirnov, I. A. Leneva, T. A. Kudryavtseva, E. B. Fayzuloev, V. A. Zaplutanov, S. V. Petlenko, et al. (+3) N. P. Kartashova, A. V. Gracheva, E. R. Korchevaya |
| 34 |
[GO] |
2021―Aug―30 |
Local antiviral activity of the drug «Thymogen®», nasal dosed spray, against SARS-CoV-2 coronavirus in vitro |
I. A. Leneva, V. S. Smirnov, T. A. Kudryavtseva, E. B. Fayzuloev, A. V. Gracheva, N. P. Kartashova, et al. (+2) V. A. Zaplutanov, S. V. Petlenko |
| 35 |
[GO] |
2021―Jun―25 |
Possibilities of Hyperinflammation Correction in COVID-19 |
I. S. Simutis, G. A. Boyarinov, M. Yu. Yuriev, D. S. Petrovsky, A. L. Kovalenko, S. A. Parfenov |
| 36 |
[GO] |
2021―Jun―25 |
Rationale for a New Outpatient Drug Therapy Algorithm in COVID-19 Patients Based on the Principle of «Multi-hit» Approach |
K. A. Zykov, E. A. Sinitsyn, A. V. Rvacheva, A. O. Bogatyreva, A. A. Zykova, T. V. Shapovalenko |
| 37 |
[GO] |
2021―Jun―25 |
Polyphenols Sourced from Terrestrial and Marine Plants as Coronavirus Reproduction Inhibitors |
N. N. Besednova, B. G. Andryukov, T. S. Zaporozhets, T. A. Kuznetsova, S. P. Kryzhanovskiy, L. N. Fedyanina, et al. (+3) I. D. Makarenkova, I. V. Galkina, M. Yu. Shchelkanov |
| 38 |
[GO] |
2021―Mai―07 |
The Efficacy and Safety of Riamilovir in the Treatment of Patients with COVID-19 |
А. U. Sabitov, Р. V. Sorokin, S. U. Dashutina |
| 39 |
[GO] |
2021―Mai―07 |
The Prospects of Succinates’ Use under Hypoxic Conditions in COVID-19 |
Yu. Р. Orlov, V. V. Afanasyev, I. A. Khilenko |
| 40 |
[GO] |
2021―Mai―07 |
Baricitinib in the Treatment of Patients with COVID-19: A Review of International Data and Analysis of Clinical Results in the Russian Population |
А. I. Zagrebneva, Е. А. Baryakh, Е. I. Zhelnova, N. G. Poteshkina, I. Р. Beloglazova, Z. Yu. Mutovina, et al. (+8) I. V. Samsonova, Е. А. Kovalevskaya, V. V. Parshin, V. V. Pshenichnikova, D S. Fomina, Т. S. Kruglova, М. А. Lysenko, М. А. Dranitsyna |
| 41 |
[GO] |
2021―Feb―15 |
Cytokine Storm in the Novel Coronavirus Infection and Methods of its Correction |
A. V. Ershov, V. D. Surova, V. T. Dolgikh, T. I. Dolgikh |
| 42 |
[GO] |
2021―Feb―15 |
Clinical Efficiency and Safety of Riamilovir for Treating Patients with SARS-CoV-2 Infection |
K. V. Kasyanenko, O. V. Maltsev, K. V. Kozlov, I. I. Lapikov, N. I. Lvov, V. S. Sukachev, et al. (+3) K. V. Zhdanov, P. V. Sorokin, A. K. Ratnikova |
| 43 |
[GO] |
2020―Nov―23 |
Practical Experience of Using Riamilovir in Treatment of Patients with Moderate COVID-19 |
A. U. Sabitov, V. V. Belousov, A. S. Edin, E. V. Oleinichenko, E. P. Gladunova, E. P. Tikhonova, et al. (+3) T. Yu. Kuzmina, Yu. S. Kalinina, P. V. Sorokin |
| 44 |
[GO] |
2020―Jun―08 |
Antiviral Activity of Kagocel® in vitro Against Virus SARS-CoV-2 |
S. Ya. Loginova, V. N. Shchukina, S. V. Savenko, S. V. Borisevich |
| 45 |
[GO] |
2020―Mai―25 |
Studying the Effectiveness of Ribavirin® in the Experimental Form of Severe Acute Respiratory Syndrome |
S. Ya. Loginova, V. N. Shchukina, S. V. Borisevich, R. A. Hamitov, V. A. Maksimov |
|
